Apomorphine Hydrochloride Market Size, Share, Growth, And Industry Analysis, By Type (Injection, Tablets, Thin-Film, And Nasal Powder (Pipeline)), By Application (Parkinson’s Disease and Erectile Dysfunction), Regional Insights and Forecast From 2025 To 2034

• 

  Request a Free sample to learn more about this report

APOMORPHINE HYDROCHLORIDE MARKET OVERVIEW

The global Apomorphine Hydrochloride Market was valued is expected to rise to USD 0.33727 billion in 2025, eventually reaching USD 0.5504 billion by 2034, expanding at a CAGR of 6.31% from 2025 to 2034.

The United States Apomorphine Hydrochloride market size is projected at USD 0.1138 billion in 2025, the Europe Apomorphine Hydrochloride market size is projected at USD 0.0782 billion in 2025, and the China Apomorphine Hydrochloride market size is projected at USD 0.1037 billion in 2025.
Apomorphine hydrochloride is a non-selective dopamine agonist that helps activate both D2-like and, to an extreme extent, D1-like receptors. It acts as an a-adrenergic and 5-HT2 antagonist with high affinity. It is a chemical compound that is historically a decomposition product of morphine. It is prepared by boiling morphine with concentrated acid, and thus, it has the suffix -morphine. Generally, apomorphine does not contain morphine or morphine’s skeleton; it does not bind to opioid receptors.

Apomorphine hydrochloride is used in the treatment of Parkinson’s disease and dysfunction. Parkinson’s disease is also known as a progressive neurodegenerative disorder and it affects the dopaminergic neurons in the brain. It is used to relieve pain from moderate to severe levels. The morphine extended-release capsules and tablets can only be used to cure severe uncontrollable pain by any other medications. 

KEY FINDINGS

COVID-19 IMPACT

Demand and Supply Chain Disturbance Hindered the Market Expansion

The sudden outbreak of the pandemic caused disruption in demand and supply chain. The manufacturing industries were shut which caused a disturbance in the manufacturing rate. The customer’s demand could not be fulfilled due to the transportation shutdown. The strict regulations and guidelines by the government did not allow any manufacturing or transportation to resume. The semiconductor and electronics industry was shut down during the pandemic, which hampered the growth of the market.

LATEST TRENDS

Rising Trials by Pharmaceuticals to Accelerate Market Growth

An increase in ongoing clinical trials being conducted by various pharmaceuticals and rising special designation from the regulatory authorities are anticipated to boost growth in the market. Moreover, the higher demand for disease-specific treatment is also expected to boost market growth. 

• According to ClinicalTrials.gov, as of July 2025, there are 17 registered clinical trials focusing on apomorphine-based drug delivery systems, including nasal spray and thin-film formats under Phase I and II evaluations.

• As per the U.S. FDA Orphan Drug Designations and Approvals database, apomorphine received 3 orphan drug designations between 2021–2024 specifically targeting Parkinson's disease-related motor fluctuations.

Request a Free sample to learn more about this report

APOMORPHINE HYDROCHLORIDE MARKET SEGMENTATION

By Type

By type, the market is segmented–into injection, tablets, thin-film, and nasal powder (pipeline). 

By Application

Based on application, the market is classified into Parkinson’s disease and erectile dysfunction.

DRIVING FACTORS

Rising Prevalence of Disease to Increase Market Growth

The consistently rising prevalence of diseases is anticipated to bolster growth in the market. Parkinson’s disease drugs experienced increased product demand due to the rising number of patients globally. Additionally, the expanded research and support from the government and the presence of potential pipeline products are forecasted to boost the sale of Parkinson’s disease drugs. 

Use of Apomorphine Hydrochloride as a Receptor to Boost Product Demand

Apomorphine hydrochloride has various use in the treatment of various ailments. It is also used in veterinary practices and utilized as an emetic agent. It includes vomiting to manage poisoning in dogs and other animals. It helps in controlling the poison in the animals by inducing vomiting. It acts as a receptor of dopamine. 

• According to the Parkinson’s Foundation, more than 10 million people globally live with Parkinson’s disease, with over 1 million in the United States alone, fueling the demand for dopaminergic agonists like apomorphine.

• As per WHO's 2022 Global Health Estimates, neurological disorders, including Parkinson’s, are the second-leading cause of death globally and contribute to 16.8% of all years lived with disability (YLDs), pushing demand for therapeutic interventions.

RESTRAINING FACTORS

Risk Factors Coupled with The Intake of Medicine to Affect Market Growth

The consumption of apomorphine hydrochloride without a doctor’s prescription may affect your health and cause nausea, headache, drowsiness, yawning, pale skin, runny nose, dizziness, and hallucinations. These are the side effects of consuming the medicines or tablets that can be noticed at the beginning stage. Consuming it for a long-time may show uncontrolled movements, muscle cramps, depression, trouble sleeping, or hallucinations. These side-effects are estimated to limit the apomorphine hydrochloride market growth. 

• As stated by the European Medicines Agency (EMA), up to 30% of apomorphine users experience adverse effects such as nausea, yawning, and somnolence during the early treatment phase.

• According to the U.S. National Library of Medicine, long-term use of apomorphine has been associated with 13–15% incidence of hallucinations and impulse control disorders, restricting broad-based prescription.

• Request a Free sample to learn more about this report

•  

APOMORPHINE HYDROCHLORIDE MARKET REGIONAL INSIGHTS

North America To Dominate Due To Prevalence of Chronic Diseases Among Population

North America is most likely to dominate the global market due to the rising demand for high-quality industrial valves in healthcare and pharmaceuticals. The growth of the region is also attributable to the presence of major players and the high prevalence of diseases in the general population. Additionally, the government's increasing number of research partnerships and beneficial initiatives are forecasted to be growth drivers in the market. 

Europe is also anticipated to show sizeable growth in the global market backed by the increased expenses on research and development, high incidences of Parkinson’s disease, and steady rise in the elderly population

KEY INDUSTRY PLAYERS

Key Players to Emphasize On Portfolio Development to Gain a Competitive Advantage

 Key players are anticipated to invest in research and development of the product to gain more customers in the global market. The major companies also strive to impact the market by launching new products and gaining mergers and collaborations. Companies are expected to emphasize on-demand and supply chains by offering a quick supply of the product in the market. These strategies are anticipated to gain higher growth in the apomorphine hydrochloride market and enhance the company's product portfolio. 

• Supernus Pharmaceuticals (U.S.): In 2024, the company distributed over 2.5 million apomorphine injections across 48 states under its branded Parkinson’s treatment program.

• Britannia Pharmaceuticals STADA (U.K.): The firm supplies apomorphine products to 92% of NHS Trusts in the U.K. treating Parkinson's patients with advanced-stage motor symptoms.

List of Top Apomorphine Hydrochloride Companies

• Supernus Pharmaceuticals (U.S.)
• Britannia Pharmaceuticals STADA (U.K.)
• Ever Pharma (Austria)
• Evolan Pharma AB (PharmSwed) (Sweden)
• Tianjin Tianwei Pharmaceutical (China)
• Sunovion (U.S.)

INDUSTRY DEVELOPMENT

• April 2021- Optimus Pharma announced that they received the approval for their drug Safinamide from DCGI. Safinamide as an adjunctive treatment for patients suffering from Parkinson’s disease experiencing “off” episodes. The company also announced its contribution to delivering strong treatment for Parkinson’s disease in India. 

REPORT COVERAGE

The report offers a description of the product and its applications, benefits, and side effects. The market report provides insights and situations of the key players. The new strategies adopted by the key companies are covered in this report. Major key players and their headquarters are mentioned in the report to offer market insights and represent apomorphine hydrochloride market share. This report includes the factors responsible for the growth of the market and the factors expected to limit the apomorphine hydrochloride market growth.